Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd

<< Previous

Bullboard Posts

Next >>

Post by WarrantOfficeron Dec 05, 2023 12:26pm

237 Views

Post# 35769270

From Last PR

In response to client demand, Voyageur is currently working with Alberta Veterinarian Laboratories (AVL) and its subsidiary Solvet https://solvet.ca/, to accelerate the formulation and testing of the remaining products that the market requires to ensure supply chain security for our clients. AVL is currently formulating the next 3 products with Health Canada licences; MultiXBa, MultiXs and MultiXthin. Upon completion of our full suite of products, Voyageur will begin penetrating the Canadian radiology market.

I remain critical of present managements ability to push this project forward. They inform us on 14 Sept 2023 that they are accelerating the formulating and testing of the remaining products after 2 1/2 years since our fifth Health Canada approval. They are just getting their planning together in Sept 2023 to accelerate the testing?

Further, it does not take much clairvoyance to predict the fact to entice new customers you must offer a complete product line to ensure customer stability in the marketplace.

Still holding a large position in this company, but becoming more skeptical of managements ability. I would humbly tip my hat to management if they can prove me wrong.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 21, 2024